

FOXO3 regulates Smad3 and Smad7 through SPON1 circular RNA to inhibit idiopathic pulmonary fibrosis

Hailong Li

The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Key Laboratory of Molecular Drug Research, Nankai University,

Jin He

Nankai University

Ruotong Zhang

Nankai University

Yiyang Wei

Nankai University

Shanshan Zhang

Nankai University

Xuefen Chen

Characteristic Medical Center of the Chinese People's Armed Police Force

Xiaoping Li

Tianjin First Central Hospital

Rui Yu

Beijing Institute of Biotechnology

Xiaohe Li

The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Key Laboratory of Molecular Drug Research, Nankai University, <https://orcid.org/0000-0003-4315-5953>

Xianfeng Zhang

Tianjin Beichen Hospital

Cheng Yang

Nankai University

Honggang Zhou (✉ honggang.zhou@nankai.edu.cn)

Nankai University

Article

Keywords: Idiopathic pulmonary fibrosis, FOXO3, circSPON1, Smad3, Smad7

Posted Date: September 21st, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-900230/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **FOXO3 regulates Smad3 and Smad7 through SPON1 circular RNA to inhibit**
2 **idiopathic pulmonary fibrosis**

3
4 Hailong Li^{1,2}, Jinhe Li^{1,2}, Ruotong Zhang^{1,2}, Yiyang Wei^{1,2}, Shanshan Zhang^{1,2}, Xuefen Chen³,
5 Xiaoping Li⁴, Rui Yu⁵, Xiaohe Li^{1,2}, Xianfeng Zhang⁶, Honggang Zhou^{1,2,*}, Cheng Yang^{1,2,*}
6

7 ¹The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Key
8 Laboratory of Molecular Drug Research, Nankai University, ²High-throughput Molecular Drug
9 Screening Centre, Tianjin International Joint Academy of Biomedicine, ³Department of
10 Respiratory Medicine, Characteristic Medical Center of the Chinese People's Armed Police Force,
11 Tianjin, China. ⁴Department of thoracic surgery, Tianjin First Central Hospital, School of
12 Medicine, Nankai University, Tianjin 300192, China ⁵Beijing Institute of Biotechnology. 20
13 Dongdajie Street, Fengtai District, Beijing, China. ⁶Department of Respiratory and Critical Care
14 Medicine, Tianjin Beichen Hospital

15 *Correspondence: Honggang Zhou (honggang.zhou@nankai.edu.cn) Cheng Yang
16 (yangcheng@nankai.edu.cn)
17

18 **ABSTRACT**

19 Forkhead box protein O3 (FOXO3) has good inhibition ability toward fibroblast
20 activation and extracellular matrix, especially for the treatment of idiopathic
21 pulmonary fibrosis. How FOXO3 regulates pulmonary fibrosis remains unclear. In
22 this study, we reported that FOXO3 had binding sequences with F-spondin 1 (SPON1)
23 promoter, which can activate its transcription and selectively promote the expression
24 of SPON1 circRNA (circSPON1) but not mRNA expression. We further demonstrated
25 that circSPON1 was involved in the extracellular matrix deposition of HFL1. In the
26 cytoplasm, circSPON1 directly interacted with TGF- β -induced Smad3 and inhibited
27 the activation of fibroblasts by inhibiting nuclear translocation. Moreover, circSPON1
28 bound to miR-942-5p and miR-520f-3p that interfered with Smad7 mRNA and
29 promoted Smad7 expression. This study revealed the mechanism of FOXO3 in the
30 occurrence and development of pulmonary fibrosis. Potential therapeutic targets and
31 new insights into the diagnosis and treatment of idiopathic pulmonary fibrosis based
32 on circRNA were also provided.
33

34 **Keyword:** Idiopathic pulmonary fibrosis, FOXO3, circSPON1, Smad3, Smad7
35

36 **INTRODUCTION**

37 Idiopathic pulmonary fibrosis (IPF), a chronic and progressive pulmonary interstitial
38 disease with unknown etiological causes, currently lacks effective treatment methods
39 apart from lung transplantation, and its median survival time after diagnosis is 2–3
40 years on average ^{1,2}. The histopathological manifestations of IPF are the remodeling
41 of lung-tissue structure, including the excessive proliferation of fibroblasts and
42 deposition of extracellular matrix (ECM) ³. In IPF, the abnormal proliferation and
43 differentiation of fibroblasts into myofibroblasts lead to the excessive production of
44 ECM components, leading to lung parenchyma and loss of lung function ^{4,5}. Forkhead

45 box protein O3 (FOXO3) plays an important role in fibrosis development and IPF
46 treatment, and FOXO3 expression in myofibroblasts is significantly reduced ⁶.
47 Evidence indicates that FOXO3 inhibits fibroblast activation and ECM deposition ⁷,
48 but its regulatory mechanism remains unclear. No studies have shown that FOXO3
49 has binding sequences on ECM-related gene promoters.

50 Abnormal tissue repair and fibrotic hyperplasia in IPF are affected by various
51 cytokines in the microenvironment, among which the transforming growth factor- β 1
52 (TGF- β 1) signaling pathway is currently recognized as the most important fibrotic
53 signal and plays a master-switch role in the pathogenesis of pulmonary fibrosis ⁸.
54 TGF- β binds to TGF- β type-II receptor, and the serine/threonine of TGF- β type-I
55 receptor is activated to transport the signal to the nucleus through the downstream
56 effector Smad protein, which regulates gene transcription ⁹. Smad3, a
57 receptor-regulated Smads (R-Smads), phosphorylates and forms a complex with
58 Smad4 to transmit signals into the nucleus. Smad7, which is an inhibitory Smads
59 (I-Smads), regulates TGF- β signal through a negative feedback mechanism ¹⁰.
60 Therefore, the regulation of the R-Smads and I-Smads pathways is important to
61 inhibit TGF β activation.

62 A study published in *Cell* shows that SPON1, a secreted protein expressed at high
63 levels in the floor plate, promotes nerve-cell adhesion and neurite elongation ¹¹. The
64 C-terminal type-1 repetitive response (TSR) domain of this protein has been shown to
65 mediate many of its biological activities, including the induction of PGE2, ECM
66 binding, and cell survival. Evidence indicates that the TSR domain of SPON1 can also
67 act as a functional TGF- β activation domain ¹². In osteoarthritis, SPON1 can activate
68 latent TGF- β in the lesion area to induce cartilage degradation, and the addition of
69 SPON1 in the culture of cartilage explants can activate latent TGF- β 1 ¹³. In recent
70 years, noncoding RNA has been extensively studied, and circ-RNA has gradually
71 become a hot research topic in recent years. Meanwhile, circ-RNAs are
72 single-stranded noncoding RNA molecules formed by covalently binding the 3' and 5'
73 ends through reverse splicing ^{14,15}. Evidence indicates that circ-RNA is involved in the
74 multifaceted fibrosis process of various organs, including the heart, liver, lungs, and
75 kidneys ¹⁶⁻¹⁹. Moreover, circ-RNA reportedly competes with mRNA precursor
76 splicing during gene transcription ²⁰ and plays an important role in various biological
77 functions by acting on miRNA sponges and binding to RNA-binding proteins ²¹.
78 Although SPON1 activates the TGF- β signaling pathway, the role of SPON1 and its
79 circ-RNA in pulmonary fibrosis remains unclear.

80 In the present study, we demonstrated that FOXO3 can activate SPON1 transcription,
81 selectively promote the expression of SPON1 circRNA, and inhibit the expression of
82 SPON1 mRNA. We demonstrated that circSPON1 expression decreased in the
83 pulmonary fibrosis model group. We then confirmed that circSPON1 expression
84 decreased in the pulmonary fibrosis model group, and that circSPON1 overexpression
85 inhibited ECM deposition. Circ-spon1 inhibited ECM deposition by binding to Smad3
86 and adsorbing miRNA targeting Smad7. In vivo, we further demonstrated that
87 FOXO3 alleviated IPF in mice by promoting circSPON1 expression. Here, we
88 explored a novel FOXO3/circSPON1 regulatory mechanism that can provide a

89 potential target for the treatment of IPF.

90

91 **MATERIALS AND METHODS**

92 **Cell culture and transfection**

93 Human fetal lung fibroblast (HFL1) cells and human embryonic kidney (HEK293T)
94 cells were purchased from the Cell Resource Center of Shanghai Institutes for Life
95 Sciences, Chinese Academy of Sciences. The HFL1 and HEK293T cells were
96 cultured in F12K and DMEM medium containing a mixture of 10% FBS and 1%
97 penicillin–streptomycin, respectively, and placed in a 37 °C incubator containing 5%
98 CO₂. The growth of HFL1 cells was observed for a fixed period.

99 Information on the plasmids, siRNA, miRNA mimic, and probe sequence is provided
100 in Supplementary Table S1. All plasmids, miRNA mimics, and siRNA were
101 transfected with liposome 8000 (Beyotime Biotechnology, Beijing). pcDNA 3.1 (+)
102 circSPON1 Mini, si-circSPON1, and miRNA mimic were synthesized by
103 GenePharma.

104 **Chromatin immunoprecipitation assay**

105 Chromatin immunoprecipitation (ChIP) sequencing (ChIP-seq) was used to detect the
106 interaction of the transcription factor FOXO3 with genes in HFL1 cells (1×10⁷).
107 HFL1 cells were fixed at 37 °C with a final concentration of 1% formaldehyde for
108 10 min. Crosslinking was terminated with glycine, and the cells were washed twice
109 with precooled phosphate buffer saline (PBS) containing 1 mM PMSF in an ice bath.
110 SDS lysis buffer containing 1 mM PMSF was prepared in an ice bath for 10 min to
111 complete cell lysis. The previous ultrasonic treatment conditions were optimized
112 successfully. The samples were then added with 1 μg of FOXO3 (Abcam) antibody,
113 slowly shaken at 4 °C, and mixed overnight. Finally, 60 μL of protein A+G
114 Agarose/Salmon Sperm DNA (Beyotime Biotechnology, Beijing) was added to obtain
115 free DNA by using the reverse cross-linking protein/DNA complex. Free DNA was
116 sequenced by GENEWIZ Biological Technology Co., Ltd.

117 **Quantitative reverse-transcription-PCR**

118 Trizol reagent was used to extract total RNA from HFL1 cells and lung tissues. HFL1
119 nuclear and cytoplasmic components were determined using a Nuclear and
120 cytoplasmic Separation Kit (Beyotime Biotechnology, Beijing). To quantify mRNA,
121 miRNA, and circRNA, we performed reverse transcription using the Hifair® II
122 First-Strand cDNA Synthesis Kit (Yesen, Shanghai, China). Finally, according to the
123 instructions of Hieff UNICON® qPCR SYBR Green Master Mix (Yesen, Shanghai,
124 China), a 20 μL reaction system was used for fluorescence quantization. Each target
125 gene was compared with the corresponding internal reference gene, and the 2^{-ΔΔCt}
126 method was used for statistical analysis. The primer sequences are listed in
127 Supplementary Table S2.

128 **Dual luciferase report**

129 The recombinant plasmids used in this study included the Gaussia Luciferase report
130 clone plasmid containing the SPON1 promoter sequence
131 (pEZX-PG04-SPON1-promoter), the 3' untranslated region (UTR) of Smad7
132 (pEZX-MT05-Smad7-3' UTR), and the miRNA binding site sequence of

133 circSPON1(pEZXM-T05-circSPON1). pEZXM-PG04-SPON1-promoter and FOXO3
134 overexpression vector or FOXO3 siRNA were transfected into HFL1 cells. HEK293T
135 cells were transfected with pEZXM-T05-Smad7-3' UTR and
136 pEZXM-T05-circSPON1, as well as miRNA mimic and circSPON1 overexpression
137 vectors. Finally, gaussia luciferase and secreted alkaline phosphatase were detected
138 with a Secretase-Pair Dual Luminescence Assay Kit (GeneCopoeia Guangzhou).

139 **Mouse pulmonary fibrosis model and transfection**

140 Male C57BL/6 mice, aged 8–10 weeks, were purchased from the Laboratory Animal
141 Center of Nankai University. The feeding conditions of the experimental mice and the
142 operation of animal experiments were performed in strict accordance with the
143 regulations of "Guidelines on the Care and Use of Experimental Animals" issued by
144 the National Institutes of Health of the United States and approved by the Animal
145 Care and Use Committee of Nankai University.

146 The pulmonary fibrosis model of mice was established with a single infusion of
147 bleomycin (BLM) in trachea²². A total of 64 mice were randomly divided into eight
148 groups as follows: control group (injected intratracheally with 0.9% NaCl), BLM
149 group (injected intratracheally with of 2 U of BLM dissolved in 0.9% NaCl),
150 BLM+FOXO3 group (FOXO3 overexpression), BLM+FOXO3+circSPON1 (FOXO3
151 and circSPON1 overexpression), BLM+FOXO3+si-circSPON1 group (FOXO3
152 overexpressed, circSPON1 silenced), BLM+Vector group (a blank vector
153 overexpressing FOXO3), BLM+NC group (a blank vector overexpressing
154 circSPON1), and BLM+si-NC group (a blank vector that silenced circSPON1).
155 FOXO3-overexpressed plasmid, circSPON1-overexpressed plasmid, si-circSPON1,
156 control vector, and DNA or RNA transfection agent (Entranster-in vivo, Engreen)
157 were intraperitoneally injected into mice every other day after 7 days of BLM tracheal
158 infusion. On the 14th day after BLM treatment, the mice were sacrificed for
159 subsequent experiments.

160 **HE staining of lung-tissue sections**

161 The lung tissues of mice were soaked and fixed overnight with 4% formal solution
162 and embedded in paraffin. HE staining was performed to prepare pathological
163 sections of lung tissue. Finally, the section was observed under a microscope and
164 photographed.

165 **Immunohistochemistry of lung tissue**

166 SPON1 was detected in lung tissues of each group through immunohistochemistry.
167 First, 4 μm-thick tissue sections were dewaxed with xylene. After eliminating the
168 endogenous catalase activity, the sections were incubated with 5% serum at 37 °C for
169 1 h, added with a drop of primary antibody (1:100), and stored overnight in a
170 refrigerator at 4 °C. On the second day, they were washed thrice with PBS solution
171 and incubated with secondary antibody at room temperature for 1 h. Finally, a
172 3,3'-diaminobenzidine kit was used for color development. The sections were
173 observed under a microscope and photographed.

174 **Determination of hydroxyproline (HYP) content**

175 HYP is one of the main components of collagen in the body and is distributed mostly
176 in skin, tendons, cartilage, and blood vessels. Thus, HYP content is an important

177 indicator reflecting the metabolism and fibrosis degree of collagen tissue. The HYP
178 content in mouse lung tissue was detected with an HYP assay kit (Solarbio, Beijing).

179 **Pulmonary-function Test**

180 Airway resistance and lung-compliance system were used to detect lung function in
181 each group. The specific determination method was as described above²³.

182 **RNA immunoprecipitation assay (RIP)**

183 HFL1 cells were lysed in precooled RIP lysate containing RNase inhibitor and PMSF
184 and then incubated with 5 µg primary antibody at 4 °C for 3 h. Then, 50 µL of Protein
185 A/G MagBeads (IP Grade) (Yesen, Shanghai, China) were added, and the mixture
186 incubated was at 4 °C for 4 h. Finally, the beads were washed with PBS, and the RNA
187 samples were extracted with Trizol. The RNA obtained was followed by reverse
188 transcription and real-time fluorescence quantitative PCR.

189 **Chromatin isolation by RNA purification (ChIRP)**

190 ChIRP is a high-throughput assay for the detection of RNA-bound DNA and proteins.
191 Biotin-labeled circSPON1 and miRNA probes were synthesized using BersinBi.
192 HFL1 cells were lysed in precooled RIP lysate containing RNase inhibitor and PMSF
193 and then incubated with 3 µg of Biotin RNA probes at 4 °C for 4 h. Then, 50 µL of
194 Streptavidin MagBeads (Yesen, Shanghai, China) were added to the sample, and the
195 mixture was incubated at 4 °C for 2 h. The beads were thoroughly washed with a
196 lysate containing RNase A and H. Finally, Western blot was used to detect the protein
197 in the sample.

198 **Fluorescence in situ hybridization (FISH)**

199 FISH is a kind of oligonucleotide probe labeled by a fluorescent group directly or by
200 biotin indirectly. We detected circSPON1, miRNA, and Smad3 through RNA FISH.
201 circSPON1 and miRNA FISH probes were synthesized in GenePharma. The specific
202 experimental method was performed according to the instructions in the RNA FISH
203 kit (GenePharma, Shanghai). Finally, a confocal microscope (LSM 800, Zeiss) was
204 used to obtain images.

205 **Western blot**

206 Total protein of mouse lung tissue and cells was extracted using RIP protein lysate
207 containing 1% PMSF. The nuclear and cytoplasmic proteins of HFL1 were extracted
208 using a Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime Biotechnology,
209 Beijing). The protein concentration of each sample was detected by BCA method. The
210 proteins were separated by SDS-PAGE gel electrophoresis, transferred onto PVDF
211 membrane, and sealed with 5% skimmed milk powder at room temperature for 1 h.
212 The PVDF membranes were then incubated overnight with COL1A1 (1:1000, Cell
213 Signaling Technology), α-SMA (1:1000; Cell Signaling Technology), FN (1:1000;
214 Cell Signaling Technology), FOXO3 (1:1000; Abcam), SPON1 (1:1000; Signalway
215 Antibody), Smad3 (1:1000; Affinity), Smad7 (1:1000; Affinity), GAPDH (1:1000;
216 Proteintech), and Lamin B1 (1:1000; Affinity) primary antibody at 4 °C. After
217 washing with TBST three times, secondary antibody (1:10000) was added and the
218 mixture was incubated at room temperature for 2 h. Finally, a chemiluminescence
219 imaging system (Tanon, Shanghai) was used to obtain protein images, and Image J
220 software was used for protein quantification.

221 **Statistical analysis**

222 Each experiment was performed at least three times independently, and data are
223 expressed as the mean \pm standard deviation (SD). Graphpad Prism 8 software was
224 used for the statistical analysis of experimental data. Two independent sample T-tests
225 were used for comparison between two groups, and one-way ANOVA was used for
226 comparison between multiple groups. $p < 0.05$ was considered statistically significant
227

228 **RESULTS**

229 **1. FOXO3 bound to the SPON1 promoter sequence**

230 To explore the transcriptional regulation mechanism of FOXO3, we analyzed
231 genome-wide gene segments interacting with FOXO3. ChIP-seq was used to study the
232 interaction of FOXO3 with DNA in HFL1 cells by using FOXO3 antibody. We
233 analyzed the genomic characteristics of FOXO3 and revealed the binding motif of
234 FOXO3 on SPON1 and its promoter, as shown in Figure 1A. The visual results of
235 ChIP-seq read comparison on the genome are shown in Supplementary Figure S1.
236 Next, we designed primers for the SPON1 promoter sequence and verified the
237 combination of FOXO3 with the SPON1 promoter sequence through ChIP-PCR
238 (Figure 1B). The result validated the ChIP-seq findings. Additionally, we constructed
239 a dual luciferase reporting system containing the SPON1 promoter sequence to
240 explore the effects of FOXO3 on SPON1 promoter activity. Results showed that
241 FOXO3 overexpression significantly increased luciferase activity, whereas silencing
242 FOXO3 significantly decreased luciferase activity (Figure 1C). Overall, these
243 experimental results proved that FOXO3 had binding sequences with SPON1
244 promoter. To investigate the expression and role of SPON1 in pulmonary fibrosis, we
245 analyzed SPON1 expression in BLM-induced mouse lung tissue. Although FOXO3
246 regulated the activity of SPON1 promoter, Western blot and immunohistochemical
247 results showed no significant difference in SPON1 expression existed in the lung
248 tissues of BLM-induced pulmonary fibrosis mice at 14 and 21 days (Figures 1D and
249 1E). Therefore, we speculated that the circRNA produced by SPON1 may play an
250 important role in the occurrence and development of IPF.

251 **2. circSPON1 expression decreased during fibrosis formation**

252 We further predicted several SPON1 circRNAs on the circBase site. Five circRNAs
253 (hsa_circ_0095395, hsa_circ_0095396, hsa_circ_0095397, hsa_circ_0095398, and
254 hsa_circ_0095399) of SPON1 host genes were identified in HFL1 (Supplementary
255 Figure S2A). The circSPON1 subtype (Hsa_circ_0095396, called circSPON1 in
256 subsequent studies) located in the human genome Chr11:13962723-14268133 was the
257 cyclization product of exons 2 to 5 of SPON1 gene (Figure 2A and Supplementary
258 Figure S2B). qRT-PCR results showed that RNase R could significantly degrade
259 Spon1 linear mRNA but not circRNA (Figure 2B). The primers were designed to
260 amplify the circ-SIRT1 reverse-splicing site sequence, and the RT-PCR product was
261 purified and sequenced to determine the circSPON1 junction sequence
262 (Supplementary Figure S2C). We then confirmed that circSPON1 was extensively
263 present in the heart, liver, spleen, lung, kidney, and colon tissues of mice. Using a
264 BLM-induced pulmonary fibrosis model, we found that the circSPON1 level in the

265 lung tissue gradually decreased on days 14 and 21 of collagen deposition and
266 pathological damage compared with the normal group ($p < 0.05$; Figure 2D–2F).
267 circSPON1 levels were also significantly reduced in primary IPF cells compared with
268 those in HFL1 cells ($p < 0.05$; Figure 2G). TGF- β 1 induced a significant increase in
269 collagen-related protein expression and a significant decrease in circSPON1 level in
270 HFL1 cells (Figures 2H and 2I). These results indicated that circSPON1 may be
271 involved in fibrosis formation.

272 **3. FOXO3-regulated circSPON1 inhibited the activation of fibroblasts**

273 To determine how FOXO3 regulated SPON1 circRNA in HFL1, we detected the
274 levels of pre-mRNA, mRNA, and circSPON1 of SPON1. A schematic of specific
275 primers is shown in Figure 3A. FOXO3 overexpression significantly promoted the
276 levels of SPON1 pre-mRNA and circSPON1 and inhibited the level of SPON1 mRNA.
277 Silencing FOXO3 inhibited the pre-mRNA and circSPON1 levels and promoted the
278 SPON1 mRNA levels (Figures 3B–3D). Meanwhile, FOXO3 overexpression in HFL1
279 cells significantly inhibited SPON1 expression, and the silencing of FOXO3
280 significantly promoted SPON1 expression (Figure 3E). We demonstrated that the
281 endogenous expression of circSPON1 was induced by SPON1.

282 To determine the function of circSPON1 in HFL1 cells, circSPON1 overexpression
283 plasmid (pcDNA 3.1 circSPON1 mini) and silenced-RNA (si-circSPON1) were
284 designed. The transfection of overexpressed plasmid and siRNA in HFL1 cells
285 significantly promoted or inhibited circSPON1 levels, respectively, but had no effect
286 on SPON1 mRNA (Supplementary Figure S3). TGF β significantly promoted the
287 mRNA and protein levels of COL1A1, α -SMA, and FN compared with the normal
288 group ($p < 0.05$), and circSPON1 overexpression significantly inhibited the promotion
289 of TGF- β on COL1A1, α -SMA, and FN (Figures 3F and 3H). However, circSPON1
290 silencing enhanced the stimulation of TGF β to COL1A, α -SMA, and FN (Figures 3G
291 and 3I). Taken together, these results suggested that FOXO3 promoted circSPON1
292 expression, and circSPON1 inhibited TGF- β -induced fibroblast activation.

293 **4. circSPON1 interacted with Smad3 in the cytoplasm**

294 Smad3 is the key mediator of TGF- β signal transduction in ECM production and
295 tissue fibrosis. To determine the effect of circSPON1 on the Smad3 signaling pathway,
296 the cytoplasm and nucleus of HFL1 were extracted. Results showed that TGF- β
297 inhibited Smad3 expression in the cytoplasm and promoted Smad3 expression in the
298 nucleus. However, circSPON1 overexpression significantly reversed the above results
299 (Figure 4A) and circSPON1 silencing significantly promoted the above results (Figure
300 4B). Subsequently, we found that circSPON1 was primarily expressed in the
301 cytoplasm, and circSPON1 was primarily highly expressed in the cytoplasm after the
302 transfection of pcDNA 3.1 (+) circSPON1 mini (Figure 4C). Therefore, we
303 hypothesized that circSPON1 may interact with Smad3 and affect the entry of Smad3
304 into the nucleus. To verify our conjecture, we further verified the interaction between
305 Smad3 and circSPON1 through RIP experiment. Real-time PCR was performed using
306 the precipitation mixtures of IgG, SPON1, and Smad3 antibodies and specific primers
307 for circSPON1 and linear SPON1 mRNA. Results showed that Smad3 was
308 significantly enriched with circSPON1, and the circSPON1 enriched in Smad3 was

309 reduced after circSPON1 silencing, whereas more circSPON1 was enriched after
310 circSPON1 overexpression (Figures 4D and 4E). To further confirm the interaction
311 between circSPON1 and Smad3, we constructed a biotinylated DNA probe of
312 circSPON1 and incubated it with the lysate of HFL1 overexpressing and silencing
313 circSPON1. The biotin DNA probe can specifically enrich circSPON1, and the
314 enriched circSPON1 increased or decreased when circSPON1 was overexpressed or
315 silenced, respectively (Figures 4F and 4G). This finding indicated that the biotin
316 probe was specific and effective. The Smad3 pulled down by the circSPON1 probe
317 increased in HFL1 cells transfected with pcDNA 3.1 circSPON1 mini (Figure 4H) and
318 decreased following circSPON1 silencing (Figure 4I). Finally, we confirmed again
319 through FISH experiments that circSPON1 and Smad3 interacted with each other in
320 the cytoplasm and inhibited TGF- β -stimulated Smad3 translocation in HFL1 cells
321 overexpressing circSPON1 (Figure 4J). In conclusion, the above data suggested that
322 circSPON1 directly interacted with Smad3 and at least partially isolated Smad3 in the
323 cytoplasm after TGF- β stimulation.

324 **5. circSPON1 eliminated the inhibition of Smad7 protein expression by** 325 **miR-520f-3p and miR-942-5p**

326 Although circSPON1 immobilized Smad3 in the cytoplasm following TGF- β
327 stimulation, circSPON1 overexpression did not completely block the Smad3
328 translocation induced by TGF β . We hypothesized that circSPON1 may inhibit
329 pulmonary fibrosis in other ways, especially through the sponge adsorption of miRNA.
330 Smad7 is a regulator of TGF- β signaling and a cross-mediating factor of TGF- β
331 signaling, thereby playing an important role in the progression of pulmonary fibrosis
332 (10). We found that circSPON1 overexpression significantly eliminated Smad7
333 inhibition by TGF- β (Figure 5A). Ago2 protein is the RNA-induced silencing
334 complex effector protein that transports miRNA to the target mRNA to silence or
335 degrade the mRNA²⁴. RIP experiment showed that compared with IgG, Ago2
336 antibody was significantly enriched with circSPON1, and the enriched circSPON1
337 significantly increased after circSPON1 overexpression ($p < 0.05$; Figure 5B). This
338 finding proved that circSPON1 can sponge adsorb miRNA. Subsequently, we
339 predicted the target miRNA of circSPON1 and Smad7 through the Circular RNA
340 Interactome website (<https://circinteractome.nia.nih.gov/index.html>) and ENCORI,
341 respectively, and then obtained the intersection of miR-520f-3p and miR-942-5p
342 (Supplementary Figure S4). The biotin-labeled circSPON1 probe significantly pulled
343 down miR-520f-3p/miR-942-5p (Figure 5C). Similarly, the biotin-labeled
344 miR-520f-3p/miR-942-5p probe significantly pulled down circSPON1 (Figure 5D).
345 We then constructed a luciferase reporter gene containing the entire circSPON1
346 sequence and the sequence of the 3' UTR of Smad7, which had a targeted binding site
347 to miRNA (pEZX-MT05-circSPON1 and pEZX-MT05-Smad7-3' UTR). Results
348 showed that miR-520f-3p/miR-942-5p overexpression significantly inhibited the
349 luciferase activities of Luc-circspn1 and luc-Smad7 (Figures 5E and 5F), and
350 circSPON1 overexpression significantly eliminated the inhibition of the luciferase
351 activities of the overexpressed miRNA (Figure 5G). Moreover,
352 miR-520f-3p/miR-942-5p overexpression significantly inhibited Smad7 expression in

353 HFL1 cells, whereas circSPON1 overexpression significantly eliminated the
354 miR-520f-3p/miR-942-5p inhibition of Smad7 (Figures 5H and 5I). Finally, we
355 verified the interaction between circSPON1 and miR-520f-3p/miR-942-5p again
356 through FISH experiment (Figure 5J). Overall, the data suggested that circSPON1
357 adsorbed miR-520f-3p/miR-942-5p and promoted Smad7 expression.

358 **6. FOXO3 regulated circSPON1 inhibited the progression of IPF in mice**

359 To study the regulation of circSPON1 by FOXO3 in vivo and the function of
360 circSPON1 in vivo, we established a BLM-induced pulmonary fibrosis model in mice
361 (Figure 6A). Compared with the normal group, HYP content in the lung tissue of mice
362 in the model group significantly increased. Compared with the model and
363 BLM+FOXO3 groups, the HYP of BLM+FOXO3+circSPON1 group significantly
364 decreased, and the content of HYP in sicircSPON1 transfected mice was significantly
365 higher than that in the BLM+FOXO3 and model groups ($p < 0.05$; Figure 6B). The
366 pulmonary function of mice in the BLM+FOXO3 group was significantly recovered
367 (but not all indicators), and the pulmonary function of mice in the
368 BLM+FOXO3+circSPON1 group was significantly recovered ($p < 0.05$; Figures 6C–
369 6F). The pathological score of lung tissue showed that mice in the
370 BLM+FOXO3+circSPON1 group significantly decreased, even exceeding the
371 pathological score in the BLM+FOXO3 group (Figure 6G). Similarly, compared with
372 the model group, the protein and mRNA levels of COL1A1 and α -SMA in lung
373 tissues of the BLM+FOXO3 and BLM+FOXO3+circSPON1 groups significantly
374 decreased, and the BLM+FOXO3+circSPON1 group decreased the most ($p < 0.05$;
375 Figures 6H and 6I). The level of circSPON1 in the BLM+FOXO3 and BLM
376 +FOXO3+circSPON1 groups significantly increased, and the
377 BLM+FOXO3+circSPON1 group increased the most. Finally, we conducted a
378 correlation analysis of circSPON1, FOXO3, and Smad7 in lung tissues of six
379 model-group mice, and results showed that circSPON1, FOXO3, and Smad7 were all
380 positively correlated (Figure 6J). Furthermore, no significant changes were observed
381 in pathological scores and HYP content in each control group compared with those in
382 the model group ($p > 0.05$; Supplementary Figure S5). These results suggested that
383 circSPON1 overexpression can enhance the inhibitory effect of FOXO3 on fibrosis in
384 the BLM-induced mouse pulmonary fibrosis model.

385

386 **DISCUSSION**

387 Previous studies have demonstrated that FOXO3 plays an important role in reversing
388 the IPF myofibroblast phenotype in vitro and in blocking BLM-induced pulmonary
389 fibrosis in vivo^{6,7,25}. FOXO3 has been shown to exert a good inhibitory effect on
390 fibroblast activation and ECM production and can improve organ fibrosis in the
391 kidney, liver, lung, and heart^{6,26-28}. FOXO3 expression significantly decreases in
392 pulmonary fibrosis, which was also confirmed in this study. Our ChIP-seq results
393 further revealed that FOXO3 bound to SPON1 promoter, and luciferase reporter gene
394 detection confirmed that FOXO3 enhanced SPON1 promoter activity. SPON1 has
395 been shown to be closely related to the TGF- β signaling pathway, and in
396 spon1-knockout mice, component abnormalities exist in the TGF- β signaling pathway,

397 including TGF- β 1 and SMAD^{13,29}. Herein, we analyzed eight BLM-induced mouse
398 lung tissues, and results showed that no significant difference existed in SPON1
399 expression level between normal lung tissue and lung fiber tissue. Additionally, we
400 found that FOXO3 overexpression in HFL1 cells increased the mRNA level of
401 SPON1 precursor and inhibited the mRNA and protein levels. This finding suggested
402 that FOXO3 promoted the transcription of SPON1 mRNA but not translation.
403 Therefore, we speculated that FOXO3 may affect the expression and function of
404 SPON1 circRNA in pulmonary fibrosis.

405 circRNAs are covalently closed single-stranded transcripts produced by the
406 nonclassical shearing of pre-mRNA, most of which are generated by backsplicing or
407 intron processing^{30,31}. Although the low abundance of circRNAs is caused by the low
408 efficiency of backsplicing, circRNAs are resistant to exonuclease owing to the lack of
409 5' and 3' ends, so circRNAs are highly stable and can accumulate in specific tissues or
410 cells^{32,33}. Since the discovery of circRNA in 1976 by Sanger and colleagues³⁴,
411 research on circRNA has witnessed an explosive growth, with increasing evidence
412 showing the connection between circRNA and the pathological process of fibrosis³⁵.
413 In the present study, we found that the exogenous overexpression of FOXO3
414 promoted the transcription of SPON1 and the formation of spon1-related circRNA.
415 circSPON1 levels were significantly reduced in pulmonary fibrosis models, and
416 circSPON1 overexpression inhibited the expression of ECM-related proteins. Taken
417 together, these results indicated that FOXO3 and FOXO3-induced circSPON1 were
418 important in the development of pulmonary fibrosis.

419 The Smad signaling pathway is the main, central signal-transduction molecule by
420 which members of the TGF- β superfamily transmit signals to the nucleus through
421 specific receptors on the cell membrane³⁶. After TGF- β stimulation of cells, Smad2/3
422 and Smad4 aggregated to form protein complexes that entered the nucleus and thus
423 promoted ECM production and aggravated pulmonary fibrosis. However, Smad7, as
424 an I-Smads, was a key negative regulator of TGF- β signaling. Increasing evidence
425 suggests that multiple noncoding RNAs (ncRNA) are involved in the progression of
426 pulmonary fibrosis by regulating the TGF- β /Smad pathway^{37,38}. In our study, we
427 found that the exogenous expression of circSPON1 decreased Smad3 expression in
428 the nucleus and increased Smad3 expression in the cytoplasm while eliminating the
429 inhibition of Smad7 by TGF- β . The key regulatory advantage of circRNAs is that they
430 regulate gene expression by competing with mRNAs through miRNAs or by binding
431 to proteins^{39,40}. Previous studies have shown that several circRNAs including
432 circANKS1B⁴¹, Circular RNA CDR1as⁴², and circPTK2⁴³ regulate TGF β /Smad
433 signaling in breast cancer, rheumatoid arthritis, and non-small cell lung cancer.
434 However, the role of circRNAs in regulating TGF β /Smad signaling in pulmonary
435 fibrosis remains unclear. Herein, circSPON1 and Smad3 formed an inactive
436 circSPON1-Smad3 complex that inhibited the nuclear translocation of Smad3 and
437 Smad2/4 protein complex. However, we have not identified the possible binding
438 region of circSPON1 and Smad3 interaction, which will be the direction of our
439 follow-up research. Moreover, we found that FOXO3 regulated Smad7 expression
440 through an indirect pathway mediated by the circSPON1 adsorption of

441 miR-520f-3p/miR-942-5p. In fact, our results showed that circSPON1 was
442 upregulated by FOXO3 and adsorbed Smad7-targeted miRNA, promoting its
443 expression. These findings suggested that circSPON1 was a novel endogenous
444 circRNA bidirectional regulator of the TGF β /Smad signaling pathway in HFL1 cells.
445 In the BLM-induced pulmonary fibrosis mouse model, mice were treated with
446 FOXO3 and circSPON1 overexpressed plasmids and si-circSPON1 through
447 intraperitoneal injection. Results showed that FOXO3 expression promoted the
448 circSPON1 level in the body, whereas circSPON1 expression promoted the function
449 of FOXO3 to inhibit pulmonary fibrosis. FOXO3, circSPON1, and Smad7 were
450 positively correlated in vivo. These results confirmed the indirect regulation
451 mechanism of FOXO3 on Smad protein and suggested the important role of
452 circSPON1 in pulmonary fibrosis.
453 Although circSPON1 was found to mediate the effect of FOXO3 on pulmonary
454 fibrosis in this study, the specific regulatory mechanism of FOXO3 in the alternative
455 splicing of SPON1 pre-mRNA remains unclear. Whether other transcription factors
456 are involved in the regulatory process is also unknown. Furthermore, although our
457 study found that most circSPON1 existed in the cytoplasm, some circSPON1
458 remained in the nucleus. The specific function of circSPON1 in the nucleus remains
459 unclear. Hence, in the occurrence and development of pulmonary fibrosis, how
460 FOXO3 regulates the formation of circSPON1 and the function of circSPON1 in the
461 nucleus still requires further study, and we will focus on this issue in future studies.
462 In summary, we demonstrated for the first time the transcriptional regulation
463 mechanism of FOXO3 in pulmonary fibrosis. FOXO3 directly bound to SPON1 and
464 its promoter, promoted the formation of SPON1 circRNA, inhibited the nuclear
465 translocation of Smad3 through interaction with Smad3 and sponge Smad7 as the
466 targeted miRNAs to promote Smad7 expression, and ultimately inhibited the
467 progression of pulmonary fibrosis (Figure 7). Our data revealed that circSPON1
468 mediated the role of FOXO3 in pulmonary fibrosis and the role of circSPON1 in the
469 TGF/Smad signaling pathway. These findings provided a new molecular perspective
470 for treating IPF and may help develop circRNA-based diagnostic and therapeutic
471 strategies for IPF.

472

473 **ACKNOWLEDGEMENTS**

474 This work received financial support by The National Natural Science Foundation of
475 China [Grant 82070060, 82072660], the Fundamental Research Funds for the Central
476 Universities”, Nankai University (735-63211147).

477

478 **AUTHOR CONTRIBUTIONS**

479 HL.L. XH.L. HG.Z. and C.Y. designed the experiments and wrote the manuscript.
480 HJ.L. RT.Z. YY.W. and SS.Z. performed the animal and cell experiments. XP.L. R.Y.
481 XF.Z. and XF.C. touched up and revised the manuscript.

482

483 **ADDITIONAL INFORMATION**

484 Conflict of interest: The authors declare that they have no conflict of interest.

485

486 **REFERENCES**

487

488 1 Drakopanagiotakis, F., Wujak, L., Wygrecka, M. & Markart, P. Biomarkers in idiopathic
489 pulmonary fibrosis. *Matrix biology : journal of the International Society for Matrix Biology*
490 **68-69**, 404-421, (2018).

491 2 Harari, S. & Caminati, A. IPF: new insight on pathogenesis and treatment. *Allergy* **65**,
492 537-553, (2010).

493 3 Raghu, G. *et al.* Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT
494 Clinical Practice Guideline. *American journal of respiratory and critical care medicine* **198**,
495 e44-e68, (2018).

496 4 Borensztajn, K., Crestani, B. & Kolb, M. Idiopathic pulmonary fibrosis: from epithelial
497 injury to biomarkers--insights from the bench side. *Respiration; international review of*
498 *thoracic diseases* **86**, 441-452, (2013).

499 5 Selman, M., King, T. E. & Pardo, A. Idiopathic pulmonary fibrosis: prevailing and evolving
500 hypotheses about its pathogenesis and implications for therapy. *Annals of internal*
501 *medicine* **134**, 136-151, (2001).

502 6 Al-Tamari, H. M. *et al.* FoxO3 an important player in fibrogenesis and therapeutic target
503 for idiopathic pulmonary fibrosis. *EMBO molecular medicine* **10**, 276-293, 201606261
504 (2018).

505 7 Nho, R. S., Hergert, P., Kahm, J., Jessurun, J. & Henke, C. Pathological alteration of
506 FoxO3a activity promotes idiopathic pulmonary fibrosis fibroblast proliferation on type I
507 collagen matrix. *The American journal of pathology* **179**, 2420-2430, (2011).

508 8 Mackinnon, A. C. *et al.* Regulation of transforming growth factor- β 1-driven lung fibrosis
509 by galectin-3. *American journal of respiratory and critical care medicine* **185**, 537-546,
510 (2012).

511 9 Lin, X. *et al.* PPM1A functions as a Smad phosphatase to terminate TGF β signaling.
512 *Cell* **125**, 915-928, (2006).

513 10 Yan, X. & Chen, Y. G. Smad7: not only a regulator, but also a cross-talk mediator of
514 TGF- β signalling. *The Biochemical journal* **434**, 1-10, (2011).

515 11 Klar, A., Baldassare, M. & Jessell, T. M. F-spondin: a gene expressed at high levels in the
516 floor plate encodes a secreted protein that promotes neural cell adhesion and neurite
517 extension. *Cell* **69**, 95-110, (1992).

518 12 Feinstein, Y. *et al.* F-spondin and mindin: two structurally and functionally related genes
519 expressed in the hippocampus that promote outgrowth of embryonic hippocampal
520 neurons. *Development (Cambridge, England)* **126**, 3637-3648 (1999).

521 13 Attur, M. G. *et al.* F-spondin, a neuroregulatory protein, is up-regulated in osteoarthritis
522 and regulates cartilage metabolism via TGF- β activation. *FASEB journal : official*
523 *publication of the Federation of American Societies for Experimental Biology* **23**, 79-89,
524 (2009).

525 14 Du, W. W. *et al.* Identifying and Characterizing circRNA-Protein Interaction. *Theranostics*
526 **7**, 4183-4191, (2017).

527 15 Xu, M., Xie, F., Tang, X., Wang, T. & Wang, S. Insights into the role of circular RNA in
528 macrophage activation and fibrosis disease. *Pharmacological research* **156**, 104777,

529 (2020).

530 16 Yousefi, F. *et al.* TGF- β and WNT signaling pathways in cardiac fibrosis: non-coding
531 RNAs come into focus. *Cell communication and signaling : CCS* **18**, 87, (2020).

532 17 Ji, D. *et al.* Hsa_circ_0070963 inhibits liver fibrosis via regulation of miR-223-3p and
533 LEMD3. *Aging* **12**, 1643-1655, (2020).

534 18 Li, J. *et al.* CircRNA TADA2A relieves idiopathic pulmonary fibrosis by inhibiting
535 proliferation and activation of fibroblasts. *Cell death & disease* **11**, 553, (2020).

536 19 Peng, F. *et al.* circRNA_010383 Acts as a Sponge for miR-135a and its Downregulated
537 Expression Contributes to Renal Fibrosis in Diabetic Nephropathy. *Diabetes*, (2020).

538 20 Ashwal-Fluss, R. *et al.* circRNA biogenesis competes with pre-mRNA splicing. *Molecular*
539 *cell* **56**, 55-66, (2014).

540 21 Kristensen, L. S. *et al.* The biogenesis, biology and characterization of circular RNAs.
541 *Nature reviews. Genetics* **20**, 675-691, (2019).

542 22 Guo, J. *et al.* Neohesperidin inhibits TGF- β 1/Smad3 signaling and alleviates
543 bleomycin-induced pulmonary fibrosis in mice. *European journal of pharmacology* **864**,
544 172712, (2019).

545 23 Li, H. *et al.* Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice.
546 *Frontiers in pharmacology* **11**, 607075, (2020).

547 24 Winter, J., Jung, S., Keller, S., Gregory, R. I. & Diederichs, S. Many roads to maturity:
548 microRNA biogenesis pathways and their regulation. *Nature cell biology* **11**, 228-234,
549 (2009).

550 25 Nho, R. S., Peterson, M., Hergert, P. & Henke, C. A. FoxO3a (Forkhead Box O3a)
551 deficiency protects Idiopathic Pulmonary Fibrosis (IPF) fibroblasts from type I
552 polymerized collagen matrix-induced apoptosis via caveolin-1 (cav-1) and Fas. *PloS one*
553 **8**, e61017, (2013).

554 26 Luo, W. M. *et al.* Tongxinluo Protects against Hypertensive Kidney Injury in
555 Spontaneously-Hypertensive Rats by Inhibiting Oxidative Stress and Activating Forkhead
556 Box O1 Signaling. *PloS one* **10**, e0145130, (2015).

557 27 Li, A., Wang, J., Wu, M., Zhang, X. & Zhang, H. The inhibition of activated hepatic stellate
558 cells proliferation by arctigenin through G0/G1 phase cell cycle arrest: persistent
559 p27(Kip1) induction by interfering with PI3K/Akt/FOXO3a signaling pathway. *European*
560 *journal of pharmacology* **747**, 71-87, (2015).

561 28 Ricke-Hoch, M. *et al.* Opposing roles of Akt and STAT3 in the protection of the maternal
562 heart from peripartum stress. *Cardiovascular research* **101**, 587-596, (2014).

563 29 Palmer, G. D. *et al.* F-spondin deficient mice have a high bone mass phenotype. *PloS one*
564 **9**, e98388, (2014).

565 30 Chen, L. L. The expanding regulatory mechanisms and cellular functions of circular RNAs.
566 *Nature reviews. Molecular cell biology* **21**, 475-490, (2020).

567 31 Gao, Y. *et al.* Comprehensive identification of internal structure and alternative splicing
568 events in circular RNAs. *Nature communications* **7**, 12060, (2016).

569 32 Cortés-López, M. *et al.* Global accumulation of circRNAs during aging in *Caenorhabditis*
570 *elegans*. *BMC genomics* **19**, 8, (2018).

571 33 Weigelt, C. M. *et al.* An Insulin-Sensitive Circular RNA that Regulates Lifespan in
572 *Drosophila*. *Molecular cell* **79**, 268-279.e265, (2020).

- 573 34 Sanger, H. L., Klotz, G., Riesner, D., Gross, H. J. & Kleinschmidt, A. K. Viroids are
574 single-stranded covalently closed circular RNA molecules existing as highly base-paired
575 rod-like structures. *Proceedings of the National Academy of Sciences of the United*
576 *States of America* **73**, 3852-3856, (1976).
- 577 35 Yang, Y. *et al.* CircRNAs: Decrypting the novel targets of fibrosis and aging. *Ageing*
578 *research reviews* **70**, 101390, (2021).
- 579 36 Li, G. C. *et al.* TGF beta1 and related-Smads contribute to pulmonary metastasis of
580 hepatocellular carcinoma in mice model. *Journal of experimental & clinical cancer*
581 *research : CR* **31**, 93, (2012).
- 582 37 Yang, F. *et al.* Silencing long non-coding RNA Kcnq1ot1 alleviates pyroptosis and fibrosis
583 in diabetic cardiomyopathy. *Cell death & disease* **9**, 1000, (2018).
- 584 38 Che, H. *et al.* Melatonin alleviates cardiac fibrosis via inhibiting lncRNA
585 MALAT1/miR-141-mediated NLRP3 inflammasome and TGF- β 1/Smads signaling in
586 diabetic cardiomyopathy. *FASEB journal : official publication of the Federation of*
587 *American Societies for Experimental Biology* **34**, 5282-5298, (2020).
- 588 39 Memczak, S. *et al.* Circular RNAs are a large class of animal RNAs with regulatory potency.
589 *Nature* **495**, 333-338, (2013).
- 590 40 Kristensen, L. S., Hansen, T. B., Venø, M. T. & Kjems, J. Circular RNAs in cancer:
591 opportunities and challenges in the field. *Oncogene* **37**, 555-565, (2018).
- 592 41 Zeng, K. *et al.* The pro-metastasis effect of circANKS1B in breast cancer. *Molecular*
593 *cancer* **17**, 160, (2018).
- 594 42 Li, X. *et al.* Circular RNA CDR1as regulates osteoblastic differentiation of periodontal
595 ligament stem cells via the miR-7/GDF5/SMAD and p38 MAPK signaling pathway. *Stem*
596 *cell research & therapy* **9**, 232, (2018).
- 597 43 Wang, L. *et al.* Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF- β -induced
598 epithelial-mesenchymal transition and metastasis by controlling TIF1 γ in non-small cell
599 lung cancer. *Molecular cancer* **17**, 140, (2018).

600

601

602

603

604

605

606

607

608

609

610

611


612

613

614

615


616



617

618 **Figure 1.** FOXO3 bound to the SPON1 promoter sequence. **A.** The DNA binding
 619 motif of FOXO3 on SPON1 promoter was analyzed by ChIP-seq. **B.** ChIP-PCR of
 620 SPON1 promoter by anti-FOXO3 antibody in HFL1 cells. **C.** After transfection with
 621 SPON1 reporter plasmid for 48 h, the luciferase activity of HFL1 cells was detected
 622 after the overexpression or silencing of FOXO3. **D.** Western blot was used to detect
 623 SPON1 expression in the lung tissue of mice with BLM-induced pulmonary fibrosis.
 624 **E.** The SPON1 level in the lung tissue of mice with BLM-induced pulmonary fibrosis
 625 was detected by immunohistochemistry. Data are presented as the mean \pm SD. $n = 3$
 626 for B, C; $n = 8$ for D, E. * $P < 0.05$, *** $P < 0.001$.

627




628

629 **Figure 2.** circSPON1 expression decreased during fibrosis formation. **A.** Relationship
 630 among SPON1 genome DNA, mRNA, and circRNA. **B.** The circSPON1 and SPON1
 631 mRNA of HFL1 transfected with vector and circSPON1 after RNase R treatment were
 632 detected by qRT-PCR. **C.** The circSPON1 expression in each organ of mice was
 633 detected by qRT-PCR. **D.** HE staining of lung tissue of mice with BLM-induced
 634 pulmonary fibrosis. **E.** Western blot was used to detect the expression levels of
 635 COL1A1, αSMA, and FN in mouse lung tissue with BLM-induced pulmonary fibrosis.
 636 **F.** The expression levels of COL1A1, α-SMA, and FN in HFL1 cells induced by
 637 TGF-β were detected by Western blot. **G.** The level of circSPON1 in mouse lung
 638 tissue with BLM-induced pulmonary fibrosis was detected by qRT-PCR. **H.** The
 639 levels of circSPON1 in pulmonary fibrosis human primary cells and HFL1 cells were
 640 detected by qRT-PCR. **I.** The circSPON1 level in HFL1 cells induced by TGF-β was
 641 detected by qRT-PCR. Data are presented as the mean ± SD. *n* = 3. * *P* < 0.05, ** *P* <

642 0.01, *** $P < 0.001$.

643



644

645 **Figure 3.** FOXO3 regulated circSPON1 inhibited fibroblast activation. **A.**

646 Primer-design strategies for the detection of pre-mRNA, mRNA, and endogenous

647 circRNA. **B.** qRT-PCR detected the level of SPON1 pre-mRNA after expressing or

648 silencing FOXO3. **C.** qRT-PCR detected the level of SPON1 mRNA after

649 overexpressing or silencing FOXO3. **D.** qRT-PCR detected the level of SPON1

650 circRNA after overexpressing or silencing FOXO3. **E.** Western blot detected the

651 expression levels of SPON1 and FOXO3 in HFL1 cells after overexpressing or


652 silencing FOXO3. **F. G.** qRT-PCR was used to detect the expression levels of

653 COL1A1, α -SMA, and FN in HFL1 cells induced by TGF- β after overexpressing or

654 silencing FOXO3 for 24 h. **H. I.** Western Blot was used to detect the expression levels

655 of COL1A1, α -SMA, and FN in HFL1 cells induced by TGF- β after overexpressing


656 or silencing FOXO3 for 48 h. Data are presented as the mean \pm SD. $n = 3$. * $P < 0.05$,
 657 ** $P < 0.01$ versus vector or Si-NC. # $P < 0.05$, ## $P < 0.01$, ### $P < 0.001$ versus
 658 Vector+TGF- β or Si-NC+ TGF- β .
 659
 660



661

662 **Figure 4.** circSPON1 interacted with Smad3 in the cytoplasm. **A. B.** The Smad3
 663 expression in the cytoplasm and nucleus of HFL1 cells induced by TGF- β was
 664 detected by Western blot, and circSPON1 was overexpressed or silenced in HFL1


665 cells. **C.** The circSPON1 expression in the nucleus and cytoplasm of HFL1 was
 666 detected by qRT-PCR. **D. E.** RIP method was used to detect the interaction between
 667 Smad3 and circSPON1 in HFL1 transfected with circSPON1 and si-circSPON1. **F. G.**
 668 Biotin probes specifically enriched circSPON1 in HFL1 transfected with circSPON1
 669 and si-circSPON1. **H. I.** RNA pulldown verified the interaction between circSPON1
 670 and Smad3 in HFL1 transfected with circSPON1 and si-circSPON1. **J.** The
 671 circSPON1 expression in HFL1 and its interaction with Smad3 were mapped by FISH
 672 experiments. Data are presented as the mean \pm SD. $n = 3$. * $P < 0.05$, ** $P < 0.01$, ***
 673 $P < 0.001$.



674


675 **Figure 5.** circSPON1 eliminated the inhibition of Smad7 protein expression by

676 miR-520f-3p and miR-942-5p. **A.** Western blot was used to detect Smad7 expression
677 in HFL1 cells induced by TGF- β , and HFL1 cells were transfected with circSPON1.
678 **B.** RIP method was used to detect the interaction between AGO2 and circSPON1 in
679 HFL1 transfected with circSPON1 and si-circSPON1. **C.** circSPON1 biotin probe
680 specifically enriched miR-520f-3p/miR-942-5p. **D.** miRNA biotin probe specifically
681 enriched circSPON1. **E.** Construct luciferase reporter group containing the
682 circSPON1 sequence and luc-circspon1.miRNA mimics were cotransfected into
683 HEK293T cells with Luc-circSPON1. **F. G.** Construct luciferase reporter genome,
684 Luc-Smad7 containing the miRNA target sequence, miRNA mimics, and circSPON1
685 were cotransfected into HEK293T cells with Luc-Smad7. **H. I.** The Smad7 expression
686 in HFL1 cells was detected by Western blot, and HFL1 cells were transfected with
687 miRNA mimics and circSPON1. **J.** The co-localization of miR-520f-3p/miR-942-5p
688 and circSPON1 in HFL1 cells was detected by FISH assay. Data are presented as the
689 mean \pm SD. $n = 3$. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.




690

691 **Figure 6.** FOXO3-regulated circSPON1 inhibited the progression of idiopathic
 692 pulmonary fibrosis in mice. **A.** Schematic of BLM-induced pulmonary fibrosis in
 693 mice. **B.** The content of HYP in the lung tissue of each group was detected. **C. D. E. F.**
 694 Inspiratory resistance (Ri), pulmonary resistance (Re), pulmonary dynamic
 695 compliance (Cldyn), and forced vital capacity (FVC) were tested using airway



723
724
725
726
727


Supplementary Figure S1. Visual results of chip-Seq Spn1 genome comparison




728
729
730
731
732
733
734
735

Supplementary Figure S2. A. RT-PCR of circRNA isoforms produced by SPON1 host genes expressed in HFL1. B. CircSPON1 is derived from the SPON1 host gene. C. RT-PCR products were purified and sequenced to confirm the junction sequence of human and mouse circSPON1.

A



B




736

737 **Supplementary Figure S3. A. B.** qRT-PCR was used to detect the levels of
 738 circSPON1 and SPON1 mRNA after transfection of vector, circSPON1, Si-NC and
 739 Si-circspn1 in HFL1 cells.

740

741

A



B






742

743 **Supplementary Figure S4. A. B.** Schematic diagram shows the potential binding
 744 sites of miR-520f-3p/miR-942-5p on the circSPON1 transcript.

745

746



747
748
749
750
751
752

Supplementary Figure S5. A. B. HE staining and scoring of lung tissue in each group. **C.** The content of HYP in lung tissue of mice in each group was detected.

Supplementary Table S1: The primers of RT-PCR.

		Primer sequence
SPON1 Promoter	Forward	GGATCTGAGCCTCACCTCAA
	Reverse	CAGTGCACACAAACATCCCTC
CircSPON1	Forward	TTGGTCCGAGAAGACACACC
	Reverse	CCCAGCATGGTCTTCTTCCTTAT
SPON1 mRNA	Forward	GCTACTGCAGCCGTATCCTG
	Reverse	TCTGAAGTAGGAGGGAGGAGC
SPON1 pre-mRNA	Forward	CGAGGGCTACACCGAGTTC
	Reverse	CGAGCTCGCGACTGCAAG
Hsa-COL1A1	Forward	AAGCCGGAGGACAACCTTTTA
	Reverse	GCGAAGAGAATGACCAGATCC
Hsa- α -SMA	Forward	TGGGTGAACTCCATCGCTGTA
	Reverse	GTGCAATGCAACAAGGAAGCC
Hsa-FN	Forward	GTGCCCAGGAATACGCATGTA
	Reverse	CTGGTGGACGGGATCATCCT
Hsa-miR-520f-3p	RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGG ATACGACAACCCTCT
	Forward	GCCGAGAAGTGCTTCCTTTT
Hsa-miR-942-5p	RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGG ATACGACCACATGGC
	Forward	GCCGAGACAACACAGTTTTG
U6	RT	GTCGTATCCAGTGCGTGTCTGGAGTCGGCAATTGC ACTGGATACGACAAAATATGGAAC
	Forward	TGCGGGTGCTCGCTTCGGCAGC
	Reverse	TATCCAGTGCAGGGTCCG
mmc-COL1A1	Forward	CCAAGAAGACATCCCTGAAGTCA
	Reverse	TGCACGTCATCGCACACA
mmc- α -SMA	Forward	GCTGGTGATGATGCTCCCA
	Reverse	GCCCATTCGAACCACTACTCC
mmc-circSPON1	Forward	CCTGTGGAAGTCCCAAGTACA
	Reverse	CTCCCTCCTGGTTCTCTTTGA
mmc- β -actin	Forward	AGGCCAACCGTGAAAAGATG
	Reverse	AGAGCATAGCCCTCGTAGATGG
Hsa-GAPDH	Forward	CGGATTTGGTCGTATTGGGC
	Reverse	CAAATGAGCCCCAGCCTTCT

753

754

755

756

757

758

759

Supplementary Table S2: The plasmids, siRNA, miRNA mimic and FISH probe information.

Information		
Primers for plasmid		
pEZ-X-PG04.1-SPON1-promoter	Forward	GTCATTCTATTCTGGGGG
	Reverse	TTGTTCTCGGTGGGCTTGGC
pEZ-X-MT05-Smad7- 3'UTR	Forward	AGGTGGGCAAGATCAAGGGG
	Reverse	CCTATTGGCGTTACTATG
pEZ-X-MT05-circSPON1	Forward	AGGTGGGCAAGATCAAGGGG
	Reverse	CCTATTGGCGTTACTATG
pcDNA 3.1 (+) circSPON1 Mini	CMV-F	CGCAAATGGGCGGTAGGCCGTG
pEZ-M02-FOXO3	Forward	CAGCCTCCGGACTCTAGC
	Reverse	TAATACGACTCACTATAGGG
pReceiver-M02	Forward	CAGCCTCCGGACTCTAGC
	Reverse	TAATACGACTCACTATAGGG
siRNA sequence		
siNC	Forward	UUCUCCGAACGUGUCACGUTT
	Reverse	ACGUGACACGUUCGGAGAATT
si-circSPON1	Forward	AAGGAUUACCCUCUAACACTT
	Reverse	GUGUUAGAGGGUAAUCCUUTT
scramble NC	Forward	GCACCAAUACACUAUGACUTT
	Reverse	AGUCAUAGUGUAUUGGUGCTT
Hsa-miR-520f-3p mimic	Forward	AAGUGCUUCCUUUUAGAGGGUU
	Reverse	CCCUCUAAAAGGAAGCACUUUU
Hsa-miR-942-5p mimic	Forward	UCUUCUCUGUUUUGGCCAUGUG
	Reverse	CAUGGCCAAAACAGAGAAGAUU
ChIRP probe		
Oligo biotin		GGTATAAGAGTCAGTTTGCT
circSPON1 biotin probe		AGTGTTAGAGGGTAATCCTT
miR-520f-3p biotin		AGTGTTAGAGGGTAATCCTT
miR-942-5p biotin		AGTGTTAGAGGGTAATCCTT
Fish probe		
circSPON1-Cy3		AGCTGAAGTGT+TAGAGGGTAATCCT+TTG
miR-520f-3p-Fam		AACCC+TC+TAAAAGGAAGCACTT
miR-942-5p-Fam		ACT+TCTCTGT+TTCGGCCATGTG

761

762